Zortix
Ask Zortix…⌘KSign in

What finance podcasts are saying aboutModerna Inc.MRNANASDAQ

According to Zortix's podcast index, Moderna Inc. (MRNA) was discussed on 6 finance podcasts across 12 episodes in the 30 days to 27 Aug 2026, generating 12 attributed ideas — most coverage from WSJ What's News, CNBC Fast Money and Motley Fool Money.

Mentions · 7d
7
Mentions · 30d
12
Mentions · 90d
14
Episodes · 30d
12
Shows · 30d
6
Vs prior week
+3
Discussion depth
In-depth coverage
As of 24 Aug 2026
Ask Zortix about MRNA

Key facts

Exchange
NASDAQ
Sector
Biotech
Industry
Biological Products, (No Diagnostic Substances)
Headquarters
Cambridge, MA
Incorporated in
Delaware
Fiscal year ends
31 December
Formerly
Moderna Therapeutics, Inc.

Listing and registration facts from public registries · SEC EDGAR filings for MRNA. Not a rating, forecast or recommendation.

Stance mix · podcast discussion

6 BULLISH · 4 BALANCED · 2 BEARISH

Counts of attributed podcast discussion · not a rating, forecast, or recommendation

Top shows by coverage · 30 days

ShowIdeasEpisodes
WSJ What's News44
CNBC Fast Money22
Motley Fool Money22
The Options Insider Radio Network22
Forward Guidance11

Latest ideas · headlines, attributed

24 AUG3D AGOWSJ WHAT'S NEWS · IRAN
22 AUG5D AGOWSJ WHAT'S NEWS
22 AUG5D AGOTHE POMP PODCAST

Definitions

Mention
One attributed idea naming this ticker, extracted from a podcast episode and dated by the episode’s air date. How we count →
Attributed idea
A specific argument a named speaker made on a named show — never an aggregate opinion, never Zortix’s view. What qualifies →
Discussion depth
How thoroughly an idea was argued on the episode, from a brief mention to a core thesis — a description of the conversation, not a rating of the stock. The bands →
Stance mix
Counts of attributed ideas by the side each argued on this name — bullish, balanced, or bearish as the speaker put it. A tally of the conversation’s sides, never a combined score, a rating, or Zortix’s view.
MENTIONS, DEPTH, STANCE MIX & COVERAGE REFLECT PODCAST DISCUSSION · NOT A RATING, FORECAST, OR RECOMMENDATION